Prostaglandin synthesis and release by subpopulations of rat alveolar macrophages.
Alveolar macrophages are the primary phagocytic cell of lung, but are also capable of a variety of other functions, which include initiating or modulating inflammatory and immune responses through the production of soluble mediators. One such group of mediators is the eicosanoids. Further, recent data indicate that alveolar macrophages are not functionally homogeneous, but are heterogeneous with several subpopulations that differ both morphologically and functionally. Considering the apparent importance of prostaglandin synthesis and release in inflammatory and immune responses, the current study was undertaken to determine whether alveolar macrophage subpopulations differ in their ability to synthesize and release prostaglandin (PG) E, PGI2, and thromboxane A2 after stimulation by calcium ionophore A23187, zymosan, or aggregated IgG. Alveolar macrophages were harvested by bronchoalveolar lavage and were separated into 18 density-defined fractions. Density-defined alveolar macrophages (DD-AM) showed marked heterogeneity in prostaglandin synthesis and release. Maximal PGE synthesis and release was seen as a single peak after calcium ionophore A23187 and zymosan stimulation. In contrast, two peaks in PGE synthesis were seen after aggregated IgG stimulation. PGI2 synthesis was seen as a single peak generated by different DD-AM after calcium ionophore A23187 and zymosan. In contrast, aggregated IgG stimulation of subpopulations exhibited uniform synthesis and release of PGI2. Thromboxane A2 synthesis and release was maximal from a broad range of various DD-AM after calcium ionophore A23187, zymosan, and aggregated IgG stimulation. The results demonstrate that DD-AM are heterogeneous in ability to synthesize and release prostaglandins which is dependent on the stimuli. Therefore, specific subpopulations of alveolar macrophages may be central to the control of the pulmonary inflammatory response through specific eicosanoid synthesis and release.
D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D011464:Epoprostenol / Q000096:biosynthesis*; D007074:Immunoglobulin G / Q000276:immunology; D008262:Macrophage Activation / Q000187:drug effects; D008264:Macrophages / Q000145:classification* / Q000187:drug effects / Q000378:metabolism; D008297:Male; D011458:Prostaglandins E / Q000096:biosynthesis*; D011650:Pulmonary Alveoli / Q000166:cytology*; D051381:Rats; D011916:Rats, Inbred F344; D013268:Stimulation, Chemical; D013928:Thromboxane A2 / Q000096:biosynthesis*; D015054:Zymosan / Q000494:pharmacology
D007074:Immunoglobulin G; D011458:Prostaglandins E; C044411:polymeric IgG; D000001:Calcimycin; D013928:Thromboxane A2; D015054:Zymosan; D011464:Epoprostenol